Published online before print February 26, 2007, doi: 10.1161/HYPERTENSIONAHA.106.083832
(Hypertension. 2007;49:1128.)
© 2007 American Heart Association, Inc.
Original Articles |
Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure
From the Cardiorenal Research Laboratory (G.B., L.C.C.-B., A.C., J.C.B.), Mayo Clinic and Foundation, Rochester, Minn; Pharma Research Center (J.-P.S.), Bayer HealthCare AG, Wuppertal, Germany; and the Department of Cardiology (H.L.), HELIOS-Klinikum, Erfurt, Germany.
Correspondence to Guido Boerrigter, Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905. E-mail boerrigter.guido{at}mayo.edu
Soluble guanylate cyclase is a heterodimeric enzyme with a prosthetic heme group that, on binding of its main ligand, NO, generates the second messenger cGMP. Unlike conventional nitrovasodilators, the novel direct NO- and heme-independent soluble guanylate cyclase activator BAY 58-2667 is devoid of non-cGMP actions, lacks tolerance development, and preferentially activates NO-insensitive heme-free or oxidized soluble guanylate cyclase. BAY 58-2667, therefore, represents a novel therapeutic advance in mediating vasodilation. To date, its cardiorenal actions in congestive heart failure (CHF) are undefined. We, therefore, hypothesized that BAY 58-2667 would have beneficial preload- and afterload-reducing actions in experimental severe CHF together with renal vasodilating properties. We assessed the cardiorenal actions of intravenous administration of 2 doses of BAY 58-2667 (0.1 and 0.3 µg/kg per minute, respectively) in a model of tachypacing-induced severe CHF. In CHF, BAY 58-2667 dose-dependently reduced mean arterial, right atrial, pulmonary artery, and pulmonary capillary wedge pressure (from baseline 19±1 to 12±2 mm Hg). Cardiac output (2.4±0.3 to 3.2±0.4 L/min) and renal blood flow increased. Glomerular filtration rate and sodium and water excretion were maintained. Consistent with cardiac unloading, atrial and B-type natriuretic peptide decreased. Plasma renin activity (P=0.31) and aldosterone remained unchanged (P=0.19). In summary, BAY 58-2667 in experimental CHF potently unloaded the heart, increased cardiac output and renal blood flow, and preserved glomerular filtration rate and sodium and water excretion without further neurohumoral activation. These beneficial properties make direct soluble guanylate cyclase stimulation with BAY 58-2667 a promising new therapeutic strategy for cardiovascular diseases, such as heart failure.
Key Words: soluble guanylate cyclase • heart failure • drugs • oxidant stress • BAY 58-2667
Related Article:
Hypertension 2007 49: 974-976.
This article has been cited by other articles:
 |
|
 |
|
  S. Korkmaz, T. Radovits, E. Barnucz, K. Hirschberg, P. Neugebauer, S. Loganathan, G. Veres, S. Pali, B. Seidel, S. Zollner, et al. Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury Circulation, August 25, 2009; 120(8): 677 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Krieg, Y. Liu, T. Rutz, C. Methner, X.-M. Yang, T. Dost, S. B. Felix, J.-P. Stasch, M. V. Cohen, and J. M. Downey BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts Eur. Heart J., July 1, 2009; 30(13): 1607 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lapp, V. Mitrovic, N. Franz, H. Heuer, M. Buerke, J. Wolfertz, W. Mueck, S. Unger, G. Wensing, and R. Frey Cinaciguat (BAY 58-2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure Circulation, June 2, 2009; 119(21): 2781 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Boerrigter and J. C. Burnett Jr Soluble Guanylate Cyclase: Not a Dull Enzyme Circulation, June 2, 2009; 119(21): 2752 - 2754. [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Michelakis Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern Eur. Respir. J., April 1, 2009; 33(4): 717 - 721. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gheorghiade and P. S. Pang Acute heart failure syndromes. J. Am. Coll. Cardiol., February 17, 2009; 53(7): 557 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frey, W. Muck, S. Unger, U. Artmeier-Brandt, G. Weimann, and G. Wensing Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers J. Clin. Pharmacol., December 1, 2008; 48(12): 1400 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagayama, M. Zhang, S. Hsu, E. Takimoto, and D. A. Kass Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 380 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kemp-Harper and R. Feil Meeting Report: cGMP Matters Sci. Signal., March 4, 2008; 1(9): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Paulis and F. Simko LA419, a Novel Nitric Oxide Donor, Prevents Cardiac Remodeling Via the Endothelial Nitric Oxide Synthase Pathway: NO Donors as a Means of Antiremodeling Hypertension, December 1, 2007; 50(6): 1009 - 1011. [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Martin, T. Supaporn, H. H. Chen, S. M. Sandberg, Y. Matsuda, M. Jougasaki, and J. C. Burnett Jr. Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1580 - R1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, S. Genth-Zotz, and U. Hink Targeting Heme-Oxidized Soluble Guanylate Cyclase: Solution for All Cardiorenal Problems in Heart Failure? Hypertension, May 1, 2007; 49(5): 974 - 976. [Full Text] [PDF]
|
|